









市场行情
/
股票
/
nasdaq-mdwd
/

Mediwound Ltd

MDWD

18.620USD

-0.150-0.80%

收盘 12/22, 16:00（美东）报价延迟15分钟

238.74M总市值

亏损市盈率 TTM



Mediwound Ltd

18.620

-0.150-0.80%

概览公司财务分析

概览

公司

财务

分析

关于 Mediwound Ltd 公司

Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Mediwound Ltd简介



公司代码MDWD

公司名称Mediwound Ltd

上市日期Mar 20, 2014

CEOGonen (Ofer)

员工数量111

证券类型Ordinary Share

年结日Mar 20

公司地址42 Hayarkon Street

城市YAVNE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Israel

邮编8122745

电话972779714100

网址https://www.mediwound.com/

公司代码MDWD

上市日期Mar 20, 2014

CEOGonen (Ofer)

Mediwound Ltd公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Ofer Gonen

Chief Executive Officer, Director

182.10K

+84.44%

Mr. Nachum (Homi) Shamir

Independent Chairman of the Board

Mr. Jeremy Feffer

Managing Director

Ms. Hani Luxenburg

Chief Financial Officer

Mr. Stephen T. Wills, CPA

Independent Director

Dr. Ety Klinger, Ph.D.

Chief Research and Development Officer

Dr. Shmulik Hess

Chief Operating Officer, Chief Commercial Officer

Dr. Robert J. Snyder

Chief Medical Officer

Mr. David Fox

Independent Director

Dr. Vickie R. Driver, M.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Ofer Gonen

Chief Executive Officer, Director

182.10K

+84.44%

Mr. Nachum (Homi) Shamir

Independent Chairman of the Board

Mr. Jeremy Feffer

Managing Director

Ms. Hani Luxenburg

Chief Financial Officer

Mr. Stephen T. Wills, CPA

Independent Director

Dr. Ety Klinger, Ph.D.

Chief Research and Development Officer

收入明细

单位: USD更新时间: 10月6日周一

FY2024

FY2023

FY2022

FY2021

FY2020

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

USA

15.46M

76.47%

EU and other international markets

4.76M

23.53%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月5日周五

持股股东

股东类型

持股股东

占比

Clal Biotechnology Industries Ltd

11.55%

Investor AB

6.80%

Yelin Lapidot Provident Funds Management Ltd

6.32%

Rosalind Advisors, Inc.

5.84%

HOLD Alapkezelo Zrt

5.49%

其他

64.00%

持股股东

占比

Clal Biotechnology Industries Ltd

11.55%

Investor AB

6.80%

Yelin Lapidot Provident Funds Management Ltd

6.32%

Rosalind Advisors, Inc.

5.84%

HOLD Alapkezelo Zrt

5.49%

其他

64.00%

股东类型

持股股东

占比

Investment Advisor

22.91%

Holding Company

11.55%

Hedge Fund

10.81%

Investment Advisor/Hedge Fund

8.44%

Private Equity

6.80%

Venture Capital

2.95%

Corporation

2.17%

Individual Investor

1.42%

Research Firm

0.83%

其他

32.12%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

135

5.72M

44.57%

+391.20K

2025Q2

127

6.70M

61.97%

-1.10M

2025Q1

129

6.76M

62.72%

-1.01M

2024Q4

118

7.26M

67.33%

+161.02K

2024Q3

115

7.34M

70.49%

+440.76K

2024Q2

5.75M

66.40%

+288.97K

2024Q1

5.35M

61.63%

-376.56K

2023Q4

5.55M

64.63%

+32.10K

2023Q3

5.26M

71.22%

+1.01M

2023Q2

5.23M

72.67%

+954.42K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Clal Biotechnology Industries Ltd

1.48M

11.55%

Sep 30, 2025

Investor AB

872.09K

6.8%

Jun 30, 2025

Yelin Lapidot Provident Funds Management Ltd

816.74K

6.37%

-41.26K

-4.81%

Jun 30, 2025

Rosalind Advisors, Inc.

407.06K

3.17%

-99.83K

-19.69%

Jun 30, 2025

HOLD Alapkezelo Zrt

703.43K

5.49%

+703.43K

Sep 22, 2025

T. Rowe Price Associates, Inc.

369.08K

2.88%

+214.12K

+138.19%

Jun 30, 2025

Israel Biotech Fund

378.62K

2.95%

-172.63K

-31.32%

Mar 15, 2025

BlackRock Institutional Trust Company, N.A.

388.27K

3.03%

-45.72K

-10.54%

Jun 30, 2025

Deep Insight Limited Partnership

278.18K

2.17%

-273.07K

-49.54%

Mar 15, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

ARK Israel Innovative Technology ETF

1.64%

Invesco NASDAQ Future Gen 200 ETF

0.59%

iShares Micro-Cap ETF

0.03%

iShares Russell 2000 Growth ETF

0.01%

Global X Russell 2000 ETF

0.01%

ProShares Hedge Replication ETF

0.01%

iShares Russell 2000 ETF

Proshares Ultra Russell 2000

ProShares UltraPro Russell2000

ARK Israel Innovative Technology ETF

占比1.64%

Invesco NASDAQ Future Gen 200 ETF

占比0.59%

iShares Micro-Cap ETF

占比0.03%

iShares Russell 2000 Growth ETF

占比0.01%

Global X Russell 2000 ETF

占比0.01%

ProShares Hedge Replication ETF

占比0.01%

iShares Russell 2000 ETF

占比0%

Proshares Ultra Russell 2000

占比0%

ProShares UltraPro Russell2000

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

公告日期

类型

比率

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

Dec 19, 2022

Merger

7→1

常见问题

Mediwound Ltd的前五大股东是谁？



Mediwound Ltd 的前五大股东如下：
Clal Biotechnology Industries Ltd持有股份：1.48M，占总股份比例：11.55%。
Investor AB持有股份：872.09K，占总股份比例：6.80%。
Yelin Lapidot Provident Funds Management Ltd持有股份：816.74K，占总股份比例：6.37%。
Rosalind Advisors, Inc.持有股份：407.06K，占总股份比例：3.17%。
HOLD Alapkezelo Zrt持有股份：703.43K，占总股份比例：5.49%。